News / US / cnbc
Novartis Shares Slide 10% Following Third Clinical Trial Failure in Seven Days
Health Technology · Pharmaceuticals: Major · cnbc · 2026-09-08
NVS, EWL
Novartis stock dropped sharply after the company reported that its del-desiran treatment for a muscle-wasting condition failed to meet late-stage study goals.
What Happened
Clinical Trial Setbacks: Novartis shares experienced a significant decline of 10% following the announcement that its experimental drug del-desiran failed to achieve primary endpoints in a late-stage study. This development marks the third time in a single week that the pharmaceutical firm has encountered disappointing results in its drug development pipeline.
Market Reaction: Investors responded negatively to the news, leading to a double-digit percentage drop in the company's valuation during Tuesday's trading session. The rapid succession of negative clinical updates has heightened concerns regarding the firm's near-term research and development productivity.
Drug Development Challenges: The failure of del-desiran, which was being investigated for a muscle-wasting disorder, highlights the inherent volatility and risks associated with late-stage pharmaceutical testing. These setbacks represent a significant hurdle for the company's efforts to expand its portfolio of specialized therapies.
Investor Sentiment and Outlook: The market's sharp reaction underscores the sensitivity of pharmaceutical stocks to clinical trial outcomes, particularly when multiple failures occur in quick succession. Analysts and stakeholders are likely to scrutinize the company's broader research strategy as the firm navigates this difficult period of trial disappointments.